FOS and inflammatory bowel disease: Koreanaside A inhibited the activation of activator protein-1 (AP-1), NF-κB, and JAK/STAT pathways and the subsequent induction of pro-inflammatory mediators in LPS-stimulated RAW 264.7 macrophages and dextran sulfate sodium (DSS)-induced colitis mice models, thus demonstrating a potential in the treatment of inflammatory bowel disease [200].